Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 206-212

  Tetri, Sami ^a   Hakala, Johanna ^a   Juvela, Seppo ^b   Saloheimo, Pertti ^a   Pyhtinen, Juhani ^a   Rusanen, Harri ^a   Savolainen, Eeva Riitta ^a   Hillbom, Matti ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cerebral haemorrhage; Deep Vein Thrombosis; Enoxaparin; Fatal Outcome; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEMATOMA; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STROKE PATIENT; SURVIVAL RATE; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 55549108688     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.018     Document Type: Article

References (21)

1. André C., de Freitas G.R., and Fukujima M.M. Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles. Eur J Neurol 14 (2007) 21-32
2. Lacut K., Bressollette L., Le Gal G., Etienne E., De Tinteniac A., Renault A., Rouhart F., Besson G., Garcia J.F., Mottier D., and Oger E. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 65 (2005) 865-869
3. Warlow C., Ogston D., and Douglas A.S. Deep venous thrombosis of legs after strokes: Part I - Incidence and predisposing factors. Part II - Natural history. Br Med J 1 (1976) 1178-1183
4. Broderick J., Connolly S., Feldmann E., Hanley D., Kase C., Krieger D., Mayberg M., Morgenstern L., Ogilvy C.S., Vespa P., and Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: A Guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38 (2007) 2001-2023
5. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage - Part I: Spontaneous intracerebral haemorrhage. Cerebrovasc Dis 22 (2006) 294-316
6. Dickmann U., Voth E., Schicha H., Henze T., Prange H., and Emrich D. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage. Klin Wochenschr 66 (1988) 1182-1183
7. Boeer A., Voth E., Henze T., and Prange H.W. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 54 (1991) 466-467
8. Skaf E., Stein P.D., Beetmath A., Sanchez J., Bustamante M.A., and Olsson R.E. Venous thromboembolism in patients with ischemic and hemorrhagic stroke. Am J Cardiol 12 (2005) 1731-1733
9. Broderick J.P., Brott T.G., Duldner J.E., Tomsick T., and Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24 (1993) 987-993
10. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH statement on management of hypertension). J Hypertens. 21 (2003) 1983-1992
11. Teasdale G., and Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet 2 (1974) 81-94
12. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke 16 (1985) 885-890
13. Jennett B., and Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet 1 (1975) 480-484
14. Siddiqui M.A., and Wagstaff A.J. Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients. Drugs 65 (2005) 1025-1036
15. Siironen J., Juvela S., Varis J., Porras M., Poussa K., Ilveskero S., Hernesniemi J., and Lassila R. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 99 (2003) 953-959
16. on behalf of the PREVAIL Investigators. Sherman D.G., Albers G.W., Bladin C., Fieschi C., Gabbai A.A., Kase C.S., O'Riordan W., and Pineo G.F. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369 (2007) 1347-1355
17. Samama M.M., Cohen A.T., Darmon J.E., Desjarnins L., Eldor A., Janbon C., Leizorevicz A., Nguyen H., Olsson C.-G., Turpie A.G., and Weisslinger N for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341 (1999) 793-800
18. Kelly J., Rudd A., Lewis R., and Hunt B.J. Venous thromboembolism after acute stroke. Stroke 32 (2001) 262-267
19. Johnston K.C., Li J.Y., Lyden P.D., Hanson S.K., Feasby T.E., Adams R.J., Faught Jr. R.E., and Haley Jr. E.C. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. Stroke 29 (1998) 447-453
20. Hillbom M., Erilä T., Sotaniemi K., Tatlisumak T., Sarna S., and Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized double-blind study. Acta Neurol Scand 106 (2002) 84-92
21. Juvela S. Risk factors for impaired outcome after spontaneous intracerebralhemorrhage. Arch Neurol 52 (1995) 1193-1200